Headache最新文献

{"title":"American Headache Society 67th Annual Scientific Meeting June 19-22, 2025 Minneapolis, Minnesota: Late Breaking Scientific Abstracts for Headache.","authors":"","doi":"10.1111/head.14987","DOIUrl":"10.1111/head.14987","url":null,"abstract":"","PeriodicalId":12844,"journal":{"name":"Headache","volume":" ","pages":"1217-1258"},"PeriodicalIF":5.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144325309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and pharmacological characterization of novel multi- calcitonin gene-related peptide and pituitary adenylate cyclase-activating peptide receptor antagonists.","authors":"Zoe Tasma, Andrew Siow, Paul W R Harris, Margaret A Brimble, Debbie L Hay, Christopher S Walker","doi":"10.1111/head.14916","DOIUrl":"10.1111/head.14916","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to provide proof-of-concept that multi-receptor antagonist peptides can be generated by covalently linking independent antagonist peptides that block calcitonin gene-related peptide (CGRP_8-37) or pituitary adenylate cyclase-activating peptide (PACAP)/vasoactive intestinal peptide (VIP) (PACAP_6-38) activity.</p><p><strong>Background: </strong>The neuropeptides CGRP and PACAP are implicated in migraine and pain pathogenesis. CGRP and PACAP are elevated during a migraine attack, and following infusion of either peptide, patients develop migraine-like attacks. This indicates that targeting both these systems may provide therapeutic benefits. Mechanistic studies suggest that these peptides largely act independently from one another. Therefore, blocking the activity of both CGRP and PACAP simultaneously could provide a clinical advantage over individual blockade. One strategy is to develop a single antagonist capable of inhibiting the signaling of both CGRP and PACAP receptors, a multi-receptor antagonist. N-terminal truncation of CGRP and PACAP generates the antagonists CGRP_8-37 and PACAP_6-38, respectively. These are commonly used as research tools for the CGRP and PACAP receptors. These peptide antagonists were, therefore, used as the basis for the design of multi-receptor antagonists against the CGRP and PACAP receptors and to test their functionality in vitro.</p><p><strong>Methods: </strong>To generate multi-receptor antagonists, CGRP_8-37 was linked through 1,3-dipolar cycloaddition using click chemistry to PACAP_6-38 at amino acid residues 21, 34, or 38. The ability of these multi-receptor antagonists to block CGRP activity (CGRP and AMY₁ receptors) and PACAP-38, PACAP-27, and VIP activity (PAC₁, VPAC₁, and VPAC₂ receptors) was then characterized in transfected Cos7 cells. The peptides were then further examined in pain-relevant rat spinal cord cultures, as a model of endogenous receptors.</p><p><strong>Results: </strong>Multi-receptor antagonists were successfully generated, displaying similar antagonist potency to their parental antagonists in both transfected Cos7 cells and in spinal cord cultures. Interestingly, CGRP_8-37 linked to position 38 of PACAP_6-38 was a more potent antagonist of CGRP activity than CGRP_8-37.</p><p><strong>Conclusion: </strong>This study provides proof-of-concept evidence for the development of potent multi-receptor antagonists capable of blocking both CGRP and PACAP activity.</p>","PeriodicalId":12844,"journal":{"name":"Headache","volume":" ","pages":"1064-1079"},"PeriodicalIF":5.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12266638/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143491684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plain Language Summary Publication: Mild cognitive impairment in spontaneous intracranial hypotension and its rapid reversal by repair of a spinal cerebrospinal fluid leak.","authors":"Katharina Wolf, Florian Volz, Amir El Rahal, M Overstijns, Niklas Lützen, Charlotte Zander, Mukesch J Shah, Horst Urbach, Jürgen Beck","doi":"10.1111/head.14966","DOIUrl":"10.1111/head.14966","url":null,"abstract":"","PeriodicalId":12844,"journal":{"name":"Headache","volume":" ","pages":"1216"},"PeriodicalIF":5.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144109796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Postmarketing safety of migraine prophylactic monoclonal antibodies: An EudraVigilance database analysis of eptinezumab, fremanezumab, galcanezumab, and erenumab.","authors":"Victoria Nikitina, Greta Santi Laurini, Nicola Montanaro, Domenico Motola","doi":"10.1111/head.14962","DOIUrl":"10.1111/head.14962","url":null,"abstract":"<p><strong>Objectives/background: </strong>This study was undertaken to evaluate the postmarketing safety of monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide pathway used for migraine prophylaxis through pharmacovigilance data analysis by examining suspected adverse events reported in Europe. Migraine is one of the most prevalent and debilitating neurological disorders globally. The introduction of mAbs targeting the calcitonin gene-related peptide pathway has transformed migraine prophylaxis. However, their safety profiles in real-world settings are not fully established, and ongoing safety monitoring is essential, as clinical trials may not capture all potential adverse drug reactions associated with new therapies.</p><p><strong>Methods: </strong>A disproportionality analysis was carried out by analyzing postmarketing pharmacovigilance data from the EudraVigilance database, focusing on four mAbs: eptinezumab, fremanezumab, galcanezumab, and erenumab. Descriptive and statistical analyses were performed on data retrieved from the date of marketing authorization of each medicine up to June 16, 2024. The reporting odds ratio (ROR), information component, and empirical Bayes geometric mean were calculated to detect signals of disproportionate reporting comparing their safety profiles to topiramate, a standard preventive migraine treatment.</p><p><strong>Results: </strong>A total of 14,285 reports had emerged; most of them were from females and concerned patients aged 18-64 years. The most frequently reported adverse drug reactions were primarily nonserious, aligning with literature and previously established safety profiles, such as fatigue and injection site reactions. The statistical analysis revealed 15 significant disproportionality signals: 11 for eptinezumab and four for galcanezumab. Eptinezumab highlighted potential new safety signals such as palpitations (ROR = 6.93, 95% confidence interval [CI] = 3.39-14.18), oropharyngeal pain (ROR = 7.19, 95% CI = 3.40-15.24), and erythema (ROR = 12.31, 95% CI = 4.58-33.12). These findings suggest a potential class effect, warranting further investigations and highlighting the importance of continued monitoring regarding the long-term safety of mAbs.</p><p><strong>Conclusion: </strong>Almost all of the most reported and statistically significant adverse events were nonserious and consistent with the existing literature. Given the chronic nature of migraine treatment, continuous pharmacovigilance monitoring is essential to ensure their constant safe use in clinical practice.</p>","PeriodicalId":12844,"journal":{"name":"Headache","volume":" ","pages":"1080-1094"},"PeriodicalIF":5.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12266629/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144173325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identifying and predicting headache trajectories among those with acute post-traumatic headache.","authors":"Lingchao Mao, Jing Li, Todd J Schwedt, Teresa Wu, Katherine Ross, Gina Dumkrieger, Dani C Smith, Catherine D Chong","doi":"10.1111/head.14955","DOIUrl":"10.1111/head.14955","url":null,"abstract":"<p><strong>Objectives/background: </strong>Post-traumatic headache (PTH) is a common symptom following mild traumatic brain injury (mTBI). Currently, there is no identified way to accurately predict if, when, and at what pace a person will have PTH improvement. In our prior studies, we focused on predicting headache improvement at 3 months post-mTBI. However, that approach may overlook individual differences in how headaches evolve over time. This study aimed to identify individual subgroups based on their headache trajectories and to develop machine-learning (ML) models for early prediction of headache evolution.</p><p><strong>Methods: </strong>Participants with acute PTH completed a daily electronic headache diary over 3 months, recording their headache-related symptoms. Tensor decomposition was utilized to extract latent factors underlying the time-varying symptoms. We applied clustering techniques on the latent factors to identify patient subgroups with varying headache improvement trajectory. Next, we developed an ML method to classify each individual into a headache trajectory subgroup as early as possible within the 3-month interval.</p><p><strong>Results: </strong>Seventy-three individuals with acute PTH (mean age = 44.8 years, SD = 14.0; 50 females/23 males) were enrolled between 0 and 59 days post-mTBI. Data from 54 individuals were used as the training cohort for model training, and 19 individuals were used as the test cohort for model evaluation. Tensor decomposition extracted two latent factors: one factor representing the overall state of PTH severity and disability and the other representing the improvement state of these symptoms over 3 months. Clustering identified four patient subgroups with distinct headache evolution trajectories: (1) severe symptoms without improvement, (2) severe symptoms with mild improvement, (3) milder symptoms with substantial improvement, and (4) mildest symptoms with mild improvement. The proposed ML model achieved 0.80 cross-validation accuracy in classifying individuals with PTH into subgroups for the training cohort and 0.84 accuracy for the test cohort. Notably, the model required only the first 2 weeks of headache data to accurately identify the subgroup with the mildest headaches, 3 additional weeks to identify the subgroup with the most severe headaches and no improvement in 3 months, and 2 additional weeks to distinguish the remaining subgroups.</p><p><strong>Conclusion: </strong>This study identified subgroups of individuals with acute PTH with distinct headache improvement trajectories. The proposed ML method accurately classified individuals into these subgroups using the minimally necessary early headache data for each person, including detecting the subgroup with the mildest headaches at 2 weeks. This approach could offer an estimated forecast of headache burden over time and could assist clinicians with determining treatment needs and eligibility for PTH clinical trials.</p>","PeriodicalId":12844,"journal":{"name":"Headache","volume":" ","pages":"1124-1133"},"PeriodicalIF":5.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12266634/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144186939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validation of a Portuguese version of the four-item Migraine Interictal Burden Scale.","authors":"Sofia Ferrão Malheiro, Filipa Dourado Sotero, Manuel Bragança Pereira, Beatriz Nunes Vicente, Roberto Luís Mendes Franco, Sofia Duardte Rodrigues Casanosa, Jorge Miguel Ramos Ferreira, Raquel Santos Gil Gouveia, Carlos Andrade, Isabel Pavão Martins","doi":"10.1111/head.14958","DOIUrl":"10.1111/head.14958","url":null,"abstract":"<p><strong>Background: </strong>Migraine is the most common neurological disorder and the second leading cause of disability. While the impact of migraine on daily life is often assessed by the frequency and intensity of attacks, the impairment between episodes is frequently overlooked. The four-item Migraine Interictal Burden Scale (MIBS-4) is a tool that can provide information and help in the evaluation of interictal disability.</p><p><strong>Objective: </strong>To adapt and validate a translated version of the MIBS-4 for the Portuguese population.</p><p><strong>Methods: </strong>A prospective, multicentric observational study was conducted between July 2023 and February 2024 in six tertiary headache centers across Portugal. The MIBS-4 was translated and back-translated to obtain a consensus version. The scale was administered to 459 patients with migraine, and its psychometric properties were assessed through correlations with established measures, including the Migraine Disability Assessment Scale (MIDAS), 12-item Short Form Survey (SF-12), and Hospital Anxiety and Depression Scale (HADS).</p><p><strong>Results: </strong>A total of 459 patients were evaluated, including 430 women (93.7%), with an average age of 45.06 years. The MIBS-4 demonstrated good internal consistency with a Cronbach's alpha of 0.84 (95% confidence interval 0.81-0.86) and significant correlations with the MIDAS (r = 0.304, p < 0.001), SF-12 (r = 0.483, p < 0.001), and HADS (r = 0.211, p < 0.001), confirming its reliability and construct validity.</p><p><strong>Conclusion: </strong>This analysis showed that the Portuguese version of the MIBS-4 showed identical psychometric properties to the original scale and can effectively assess interictal disability in patients with migraine in Portuguese speaking populations. Its validation provides a valuable tool for clinical practice and research, enabling improved assessment of migraine burden and contributing to better patient care in lusophone countries.</p>","PeriodicalId":12844,"journal":{"name":"Headache","volume":" ","pages":"1107-1115"},"PeriodicalIF":5.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144101770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiovascular risk and triptan usage among patients with migraine.","authors":"Ido Peles, Ruth Smadar Shneyour, Eran Levanon, Yana Mechnik Steen, Ibraheem Abu Salameh, Michal Gordon, Ran Abuhasira, Victor Novack, Gal Ifergane","doi":"10.1111/head.14968","DOIUrl":"10.1111/head.14968","url":null,"abstract":"<p><strong>Background: </strong>Migraine, a neurovascular disorder evident by recurrent headaches, is associated with increased risk of ischemic vascular events, including ischemic stroke and myocardial infarction. Triptans, acute migraine-specific treatment, cause vasoconstriction, complicating treatment decisions, especially for patients with migraine with cardiovascular risk factors. This study examined associations between triptan usage and cardiovascular (CV) events in patients with migraine.</p><p><strong>Methods: </strong>This retrospective, population-based cohort study conducted in southern Israel utilized data from Clalit Health Services. Electronic medical records from January 2000 to January 2022 were analyzed to assess triptan usage and CV events within 90 days post-purchase among patients aged ≥18 years with a diagnosis of migraine based on International Classification of Diseases, Ninth Revision codes or triptan claims. Sensitivity analyses accounted for varying timeframes and usage patterns.</p><p><strong>Results: </strong>Among 26,054 patients with migraine, 12,560 (48.2%) initiated triptan therapy. The prevalence of CV risk factors including dyslipidemia, diabetes mellitus, hypertension, smoking, atrial fibrillation, and obesity was higher in the non-triptan group (standardized mean difference [SMD] = 0.028-0.289). The mean (standard deviation) number of triptan pills used per month was 1.9 (1.5), with most patients (89.5%) using 1-4 pills/month. CV events within 90 days occurred slightly more in the triptan group (5.1%) compared to the non-triptan group (4.1%, SMD = 0.047). Multivariable analysis revealed no significant association between triptan use and increased CV events (adjusted hazard ratio 0.96, 95% confidence interval 0.77-1.23), controlling for demographic variables and CV risk factors. Sensitivity analyses also showed no significant risk with triptan use across different timeframes and usage patterns, reinforcing these findings. In the triptan group, patients with CV events were more likely to use triptans frequently, with a higher average number of pills per month.</p><p><strong>Conclusions: </strong>This retrospective, population-based study found that triptan usage did not increase CV risk among patients with migraine, even in those with existing CV risk factors, where no formal contraindication exists. The study highlights the importance of considering individual risk factors when prescribing triptans, as certain subgroups may still be at higher risk.</p>","PeriodicalId":12844,"journal":{"name":"Headache","volume":" ","pages":"1095-1106"},"PeriodicalIF":5.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12266636/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144368802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global epidemiology and burden of headache disorders in children and adolescents from 1990 to 2021.","authors":"Guangshuang Lu, Shaobo Xiao, Yun Wang, Qiujie Jia, Shengnan Liu, Shengyuan Yu, Ruozhuo Liu, Wu Yang","doi":"10.1111/head.14937","DOIUrl":"10.1111/head.14937","url":null,"abstract":"<p><strong>Objective: </strong>We aimed to present an updated epidemiological overview of headache disorders among children and adolescents, utilizing the latest data from the Global Burden of Disease (GBD) 2021.</p><p><strong>Background: </strong>Large-sample epidemiological studies on headache disorders in children and adolescents have been limited due to their demographic uniqueness, with previous GBD studies rarely focusing on this age group, until the GBD 2021 study provided a significant update.</p><p><strong>Methods: </strong>A secondary analysis of headache disorder data from the GBD 2021 for individuals aged 0-<20 years was conducted. The analysis focused on estimating the prevalence, incidence, and disability-adjusted life-years (DALYs), as well as the estimated annual percentage changes (EAPCs). Data from 204 countries and regions, stratified by sociodemographic index (SDI), were included to assess variations in headache disorder metrics across different age groups, sexes, and socioeconomic settings.</p><p><strong>Results: </strong>Between 1990 and 2021, the global prevalence, incidence, and DALYs of headache disorders in children and adolescents rose by 22.79% (95% uncertainty interval [UI] 21.68-23.82%), 5.21% (95% UI 4.26-6.10%), and 24.27% (95% UI 20.35-26.91%) per 100,000 population, respectively. In 2021, 545,824,485 (95% UI 448,777,920-641,644,106) children and adolescents were affected, with a prevalence of 20.71% (95% UI 17.03-24.34%). Migraine affected 205,729,235 (95% UI 158,825,540-265,306,014) with a prevalence of 7.81%, and tension-type headache (TTH) affected 394,543,039 (95% UI 300,611,322-499,598,953) with a prevalence of 14.97%. The DALYs totaled 8,102,465 (95% UI 716,310-19,266,508), with migraine at 7,515,775 (95% UI 486,575-18,715,548), and TTH at 586,690 (95% UI 94,646-2,924,761). The 15-19 years age group had the highest prevalence (41.38%, 95% UI 32.73-50.58%), while the 10-14 years age group had the highest incidence (12.75%, 95% UI 9.09-16.72%). High SDI regions had the highest prevalence and DALYs; however, low-middle SDI regions experienced the fastest growth. Brazil had the highest prevalence (30.55%, 95% UI 26.44-34.65%); India had the most DALYs (1,716,049, 95% UI 138,743-4,051,479); the Northern Mariana Islands had the largest prevalence increase (EAPC 0.97, 95% confidence interval [CI] 0.67-1.26), and Norway had the highest DALYs increase (EAPC 1.31, 95% CI 0.98-1.64).</p><p><strong>Conclusions: </strong>Headache disorders in children and adolescents are emerging as critical public health challenges, especially in regions where resources are limited. It is essential to strengthen public health education and advocate for evidence-based strategies to reduce the burden.</p>","PeriodicalId":12844,"journal":{"name":"Headache","volume":" ","pages":"1170-1179"},"PeriodicalIF":5.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143763891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term safety and tolerability of zavegepant 10-mg nasal spray with concomitant use of anti-calcitonin gene-related peptide monoclonal antibodies or other select preventive migraine medications: Results from a phase 2/3 open-label study.","authors":"Gary Berman, Kathleen Mullin, Timothy Smith, Linda Mosher, Samantha Sweeney, Robert J Fountaine","doi":"10.1111/head.14954","DOIUrl":"10.1111/head.14954","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;To evaluate the safety and tolerability of zavegepant (ZAV) when used as needed for acute treatment of migraine in patients taking concomitant preventive migraine medications (anti-calcitonin gene-related peptide monoclonal antibodies [CGRP mAbs] or other select preventive migraine medications [OSPs]).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;People with migraine often use preventive and acute treatments concomitantly for breakthrough attacks. ZAV 10-mg nasal spray is the first intranasal, small-molecule CGRP receptor antagonist approved for the acute treatment of migraine with or without aura in adults.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;This was a subgroup analysis of data from a multicenter, single-arm, open-label, phase 2/3 clinical trial that assessed the safety and tolerability of ZAV for the acute treatment of migraine. Participants self-administered 1 ZAV dose/day as needed up to 8 times/month for up to 52 weeks to treat migraine attacks of any severity. Participants were categorized into five cohorts based on their current or concomitant use of preventive treatments: ZAV + CGRP mAbs, ZAV + OSPs, ZAV + CGRP mAbs or OSPs, ZAV monotherapy (ZAVmono), and the overall study population. Adverse events (AEs), clinical laboratory results, and vital signs data were evaluated and summarized descriptively.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;A total of 603 participants self-administered ≥1 dose of ZAV and 341 participants (56.6%) completed the study. Among the 603 ZAV-treated participants, 39 (6.5%) received ZAV + CGRP mAbs, 72 (11.9%) received ZAV + OSPs, 103 (17.1%) received ZAV + CGRP mAbs or OSPs (eight participants received both CGRP mAbs and OSPs), and 500 (82.9%) received ZAVmono. Baseline characteristics were similar across cohorts. The mean number of ZAV doses self-administered per month was similar across cohorts (3.1-3.3). The proportion of participants experiencing an AE was similar across cohorts (range: 73.6-76.9%). The most frequent AEs were dysgeusia (range across cohorts: 28.2-41.7%), nasal discomfort (9.7-15.4%), COVID-19 (7.2-8.7%), nausea (4.2-10.3%), back pain (4.4-15.4%), throat irritation (4.4-12.8%), and nasal congestion (5.2-7.7%). Most AEs had mild-to-moderate severity and resolved without treatment. The proportion of participants who discontinued due to an AE was similar across cohorts (range: 4.2-7.7%). No serious AEs related to ZAV treatment occurred. The proportion of participants who experienced a local-irritation AE was similar across cohorts (range: 49.4-51.4%), as was the proportion who experienced a hepatic-related AE (3.8-7.7%). No AEs related to medication-overuse headache, suicidality, or cardiovascular events occurred. No clinically meaningful trends in laboratory test results or vital signs were observed.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;Self-administration of ZAV 10-mg nasal spray for the acute treatment of migraine up to 8 times/month for up to 52 weeks appeared well-tolerated irrespectiv","PeriodicalId":12844,"journal":{"name":"Headache","volume":" ","pages":"1180-1189"},"PeriodicalIF":5.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144101737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Essential readings in headache medicine: Top 10 educational articles for trainees from 2022-2024.","authors":"Minali Nigam, Nan Cheng","doi":"10.1111/head.14967","DOIUrl":"10.1111/head.14967","url":null,"abstract":"","PeriodicalId":12844,"journal":{"name":"Headache","volume":" ","pages":"1051-1053"},"PeriodicalIF":5.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144186938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}